Compare Citius Pharmaceuticals Inc (CTXR) vs GoPro Inc (GPRO) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Citius Pharmaceuticals Inc vs GoPro Inc — how do they compare? Citius Pharmaceuticals Inc trades at $0.68 (market cap $20.01M), while GoPro Inc trades at $0.59 (market cap $114.41M). The key difference: GoPro Inc is far larger — about 5.7× Citius Pharmaceuticals Inc's market cap, and Citius Pharmaceuticals Inc is trading nearer its 52-week high, GoPro Inc nearer its low. Which is the better fit depends on your goals.
| CTXR | GPRO | |
|---|---|---|
Market Cap | $20.01M | $114.41M |
Sector | Health | Technology |
52-Week High | $1.82 | $2.88 |
52-Week Low | $0.48 | $0.62 |
Enterprise Value | $16.23M | $173.19M |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
CTXR is trading at $0.7126, up 5.26% today, with strong technical momentum showing bullish moving average signals. The company shows significant revenue growth potential with LYMPHIR commercialization expanding, though currently operates at substantial losses with a -823% net income margin. Analyst sentiment remains overwhelmingly positive with 83% buy ratings, reflecting optimism about the oncology pipeline and recent commercial progress.
The investment case hinges on successful LYMPHIR commercialization offsetting current losses, with strong institutional support providing runway. Key risks include execution challenges in scaling operations and the capital-intensive nature of biopharmaceutical development. The stock presents high-risk, high-reward potential for investors comfortable with clinical-stage biotech volatility.
GoPro (GPRO) trades at $0.70, down 3.53% in the last 24 hours, reflecting ongoing financial distress with a net income margin of -28.52% and negative cash flow. The stock is technically bearish, with moving averages signaling sell pressure, while recent news highlights a strategic review for a potential sale. Revenue has declined from $1.1B in 2022 to $652M in 2025, with consistent earnings misses and negative equity of -$681.61M.
The outlook hinges on the outcome of the strategic sale process, offering speculative upside if a buyer emerges, but risks include persistent cash burn, competitive pressures, and weak sales trends. Analysts are cautious, with only 21.43% recommending buy, as the company faces going-concern risks and dilution from financing activities.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Citius Pharmaceuticals Inc
Citius Pharmaceuticals is a late-stage biopharmaceutical company focused on critical care products. Its pipeline includes anti-infectives and targeted immune therapies for conditions like cutaneous T-cell lymphoma.
Read more on CTXR →About GoPro Inc
GoPro Inc is a United States-based company that is principally engaged in designing and providing cameras, mounts, drones and appliances. The company outsources a part of manufacturing to third parties in China. The company sells products across the world through its direct sales channel, which generates over half of total revenue, and indirectly through its distribution channel. The company has presence, including in the Americas, Europe, Middle East, Africa, and Asia-Pacific, with the Americas contributing over half of total revenue.
Read more on GPRO →
